News

Ottimo Pharma Raises over $140 Million in Series A Financing

Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital,…

Denmark’s new AI supercomputer Gefion ranked as 7th fastest storage systems in the world

Denmark's state-of-the-art AI supercomputer, Gefion, has achieved…

NeoPhore appoints Michael Shih as Chief Executive Officer

Highly experienced corporate development leader with a track…

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Licensing agreement gives Elevation Oncology access to Synaffix's…

Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies

New therapies will allow patients greater choice and flexibility…

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Statistically significant difference in arrested disease in leriglitazone…

iOnctura reaches new clinical milestones in uveal melanoma

Completed Phase I DIONE-01 study demonstrates clinical activity…

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225

NorthStar will supply non-carrier added Actinium-225, a radionuclide,…

Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)

EQT Life Sciences expands the Series B with additional capital,…

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics…

NICE Recommends ublituximab (BRIUMVI®▼) as an Option for Treating Relapsing-Remitting Multiple Sclerosis (RRMS)

London, UK, Barcelona, Spain and Düsseldorf, Germany – 5…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.